Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

LivaNova PLC - Ordinary Shares (NQ:LIVN)

67.71 +0.75 (+1.12%)
Streaming Delayed Price Updated: 10:47 AM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 99,572
Open 66.82
Bid (Size) 67.56 (300)
Ask (Size) 67.84 (200)
Prev. Close 66.96
Today's Range 66.76 - 68.00
52wk Range 32.48 - 67.92
Shares Outstanding 49,023,767
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Present at J.P. Morgan Healthcare Conference in January
From LivaNova PLC
Via Business Wire

Performance

YTD
+11.7%
+11.7%
1 Month
+7.6%
+7.6%
3 Month
+25.6%
+25.6%
6 Month
+26.6%
+26.6%
1 Year
+43.4%
+43.4%

More News

Read More
News headline image
LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting
From LivaNova PLC
Via Business Wire
News headline image
Earnings Scheduled For November 5, 2025 ↗
Via Benzinga
News headline image
Earnings Scheduled For August 6, 2025 ↗
Via Benzinga
News headline image
LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Present at Piper Sandler Healthcare Conference in December
From LivaNova PLC
Via Business Wire
News headline image
LivaNova’s VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid Services
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor Day
From LivaNova PLC
Via Business Wire
News headline image
LivaNova PLC (NASDAQ:LIVN) Beats Q3 2025 Estimates and Raises Full-Year Guidance ↗
Via Chartmill
News headline image
LivaNova Reports Third-Quarter 2025 Results; Raises 2025 Guidance
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Present at Wolfe Research Healthcare Conference in November
From LivaNova PLC
Via Business Wire
News headline image
Inspire Medical Systems Soars 3.9% on Groundbreaking Inspire V Clinical Data
Via MarketMinute
News headline image
LivaNova to Announce Third-Quarter 2025 Results
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Present Scientific Data at International Surgical Sleep Society 2025 Annual Meeting
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Appoints Donald Zurbay as a New Director
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Host Investor Day on November 12, 2025
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Present at Baird and Morgan Stanley Global Healthcare Conferences in September
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Launches Essenz Perfusion System in China
From LivaNova PLC
Via Business Wire
News headline image
Shopify, Astera Labs, Myriad Genetics, Grocery Outlet And Other Big Stocks Moving Higher On Wednesday ↗
Via Benzinga
News headline image
LivaNova Reports Second-Quarter 2025 Results; Raises 2025 Guidance
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Announce Second-Quarter 2025 Results
From LivaNova PLC
Via Business Wire
News headline image
CORE-VNS Study Further Validates Effectiveness of LivaNova’s VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression
From LivaNova PLC
Via Business Wire

Frequently Asked Questions

Is LivaNova PLC - Ordinary Shares publicly traded?
Yes, LivaNova PLC - Ordinary Shares is publicly traded.
What exchange does LivaNova PLC - Ordinary Shares trade on?
LivaNova PLC - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for LivaNova PLC - Ordinary Shares?
The ticker symbol for LivaNova PLC - Ordinary Shares is LIVN on the Nasdaq Stock Market
What is the current price of LivaNova PLC - Ordinary Shares?
The current price of LivaNova PLC - Ordinary Shares is 67.71
When was LivaNova PLC - Ordinary Shares last traded?
The last trade of LivaNova PLC - Ordinary Shares was at 02/18/26 10:47 AM ET
What is the market capitalization of LivaNova PLC - Ordinary Shares?
The market capitalization of LivaNova PLC - Ordinary Shares is 3.32B
How many shares of LivaNova PLC - Ordinary Shares are outstanding?
LivaNova PLC - Ordinary Shares has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.